Aura Biosciences (AURA) Net Cash Flow (2020 - 2026)

Aura Biosciences (AURA) has 7 years of Net Cash Flow data on file, last reported at $25.3 million in Q1 2026.

• Quarterly Net Cash Flow rose 286.1% year-over-year to $25.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.8 million (up 291.05% YoY) and the FY2025 annual result came in at $28.0 million, up 398.75% from the prior year.
• Net Cash Flow advanced to $25.3 million in Q1 2026, from $12.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $69.1 million in Q2 2025 to a low of -$83.1 million in Q1 2023.
• A 5-year average of -$3.7 million and a median of $6.3 million in 2024 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 1721.18% in 2025, down 1181.06% in 2025.
• Tracing AURA's Net Cash Flow over 5 years: stood at $60.3 million in 2022, then sank by 124.08% to -$14.5 million in 2023, then soared by 143.29% to $6.3 million in 2024, then soared by 93.51% to $12.2 million in 2025, then jumped by 108.03% to $25.3 million in 2026.
• The last three Net Cash Flow figures came in at $25.3 million (Q1 2026), $12.2 million (Q4 2025), and -$59.8 million (Q3 2025), per Business Quant data.